Clinical Trials

42 enrolled

Phase 1/2 Active not recruiting

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT03598998 2026-05-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

13 enrolled 12 charts

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT07302347 2026-05-26

MK-3475-G21

Phase 1/2 Recruiting

20 enrolled

Phase EARLY_PHASE1 Active not recruiting

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT04541108 2026-05-22

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

15 enrolled

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT02965716 2026-05-20

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

43 enrolled 18 charts

Melanoma

NCT05537740 2026-05-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

BreastDermatologicHead & NeckThoracic

129 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT02332668 2026-05-18

MK-3475-051

Phase 1/2 Recruiting

370 enrolled

Lymphoma, Melanoma

NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

36 enrolled

DermatologicHead & NeckThoracic

Melanoma

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Terminated

225 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07160335 2026-05-15

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

DermatologicGenitourinaryThoracic

174 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04708418 2026-05-14

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

60 enrolled

Melanoma

NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

59 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03304639 2026-05-13

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Phase 2 Completed

9 enrolled 11 charts

Carcinoma, Merkel Cell

NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

BreastDermatologicGastrointestinalSarcomaThoracic

15 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Phase 1/2 Recruiting

92 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT05581004 2026-05-11

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT02621021 2026-05-08

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

170 enrolled

Melanoma, Skin Neoplasms

NCT05155033 2026-05-08

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

DermatologicGenitourinary

78 enrolled

Carcinoma, Renal Cell, Melanoma

NCT06295809 2026-05-08

INTerpath-007

Phase 2/3 Terminated

46 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Squamous Cell, Skin Neoplasms

NCT04083599 2026-05-06

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05956041 2026-05-05

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

23 enrolled

Lymphoma, T-Cell, Cutaneous

NCT06984328 2026-05-05

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

1 enrolled

Phase 3 Active not recruiting

Melanoma, Recurrence

NCT02506153 2026-05-04

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Phase 2 Not yet recruiting

Melanoma

NCT07565285 2026-05-04

INFLECTION-003

48 enrolled

Melanoma

NCT04483778 2026-04-28

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

68 enrolled

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05764395 2026-04-27

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

7 enrolled

Melanoma

NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

DermatologicGastrointestinalHead & Neck

72 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT02562625 2026-04-23

PERM

Phase 2 Terminated

17 enrolled 14 charts

Melanoma

NCT04207086 2026-04-23

Neo PeLe

21 enrolled

Melanoma

NCT05341349 2026-04-23

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Terminated

1 enrolled

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT06153238 2026-04-23

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

322 enrolled

Phase 3 Active not recruiting

Melanoma

NCT05352672 2026-04-22

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

1,546 enrolled

Melanoma, Neoplasm Metastasis

NCT05583708 2026-04-22

iPRRT

18 enrolled

Carcinoma, Merkel Cell

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Recruiting

135 enrolled

Melanoma

NCT03149029 2026-04-21

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

16 enrolled 10 charts

Melanoma

NCT06743126 2026-04-21

SUPRAME

Phase 3 Recruiting

360 enrolled

Melanoma, Cutaneous Malignant

NCT06270706 2026-04-20

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

124 enrolled

Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03881488 2026-04-17

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Phase 1 Completed

100 enrolled

DermatologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT06947928 2026-04-17

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Phase 2/3 Recruiting

118 enrolled

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

50 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT07223424 2026-04-16

PSI-Immune